Henrim. Bounameaux

Q: What Schools Are Affiliated With Henrim. Bounameaux

Henrim. Bounameaux is affiliated with the following schools: KU Leuven, University of Washington, University of Geneva, Leiden University

Henrim. Bounameaux's AcademicInfluence.com Rankings

Henrim. Bounameaux

Philosophy

#9601

World Rank

#13186

Historical Rank

Logic

#6570

World Rank

#8099

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Henrim. Bounameaux's Degrees

Doctorate Medicine University of Geneva
PhD Medical Sciences University of Geneva

Why Is Henrim. Bounameaux Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Henrim. Bounameaux's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (5208)
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012) (3910)
Oral rivaroxaban for symptomatic venous thromboembolism. (2010) (2225)
Severity Scoring of Atopic Dermatitis: The SCORAD Index (1993) (1829)
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012) (1713)
Pulmonary embolism and deep vein thrombosis (2012) (803)
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) (681)
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer (2013) (636)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies (2013) (534)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017) (521)
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. (1988) (380)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2019) (359)
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2016) (311)
Postoperative pulmonary embolism after hospital discharge. An underestimated risk. (1992) (309)
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer (2012) (271)
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. (2005) (255)
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. (2021) (217)
RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATES (1983) (197)
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. (1986) (173)
Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. (2010) (163)
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. (1985) (162)
Impending paradoxical embolism: systematic review of prognostic factors and treatment. (2010) (158)
Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. (2000) (157)
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. (2016) (151)
Characterization of endothelial‐like cells derived from human mesenchymal stem cells (2007) (127)
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. (2016) (122)
Factor V Leiden paradox: risk of deepvein thrombosis but not of pulmonary embolism (2000) (118)
Adverse Skin Reactions to Low Molecular Weight Heparins (1999) (117)
Edoxaban: a new oral direct factor xa inhibitor. (2011) (109)
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. (2011) (105)
Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients 1 (2003) (101)
Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? No (2004) (98)
Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study (2002) (97)
Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. (2006) (96)
Superficial thrombophlebitis and deep vein thrombosis. A controversial association. (1997) (93)
Diagnosis, treatment, and prevention of pulmonary embolism : report of the WHO/international society and federation of cardiology task force (1992) (92)
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor (2014) (90)
Long-term results of the Simon nitinol inferior vena cava filter (1998) (88)
Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients: Results of the Antiplatelet Drug Resistances and Ischemic Events Study (2012) (86)
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. (1999) (85)
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study (2010) (81)
D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism (2006) (81)
Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism (2013) (75)
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. (2000) (73)
The novel anticoagulants: entering a new era. (2009) (73)
Identifying acutely ill medical patients requiring thromboprophylaxis (2006) (65)
Risk of recurrent venous thromboembolism according to baseline risk factor profiles. (2018) (63)
Treatment of venous thromboembolism with rivaroxaban in relation to body weight (2016) (62)
Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. (2011) (59)
Challenges in the diagnosis of acute pulmonary embolism. (2008) (59)
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry (2018) (58)
Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis. (1989) (57)
Purification and Partial Characterization of a Hereditary Abnormal Antithrombin III Fraction of a Patient with Recurrent Thrombophlebitis (1980) (57)
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism (2015) (53)
Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases (1994) (52)
Prevention of deep-vein thrombosis after total knee replacement (1999) (52)
Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. (1993) (51)
Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE) (2016) (50)
Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. (1997) (50)
Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. (1985) (50)
Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. (2012) (48)
Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism (2014) (47)
Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention (2002) (46)
Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER) (2008) (45)
Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). (2010) (41)
Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits. (1986) (39)
Effects of oxygen inhalation on skin microcirculation in patients with peripheral arterial occlusive disease. (1992) (38)
Out of Hospital Antithrombotic Prophylaxis after Total Hip Replacement: Low-molecular-weight Heparin, Warfarin, Aspirin or Nothing? (2002) (38)
Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry (2019) (37)
Heparin-Induced Thrombocytopenia Platelet Aggregation Studies in the Presence of Heparin Fractions or Semi-Synthetic Analogues of Various Molecular Weights and Anticoagulant Activities (1986) (37)
Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III. (1980) (35)
Adequacy of venous thromboprophylaxis in acutely ill medical patients (IMPART): multisite comparison of different clinical decision support systems (2010) (33)
Clinical investigation of skin microcirculation. (1993) (32)
The Determination of Antithrombin III (1978) (31)
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE (2020) (30)
Measurement of plasma D‐dimer is not useful in the prediction or diagnosis of postoperative deep vein thrombosis in patients undergoing total knee arthroplasty (1998) (30)
Promoter Dependence of Transgene Expression by Lentivirus‐Transduced Human Blood–Derived Endothelial Progenitor Cells (2006) (29)
An Exploratory Trial of Two Dosages of a Novel Synthetic Thrombin Inhibitor (Napsagatran, Ro 46-6240) Compared with Unfractionated Heparin for Treatment of Proximal Deep-vein Thrombosis (1997) (29)
Predicting healing of arterial leg ulcers by means of segmental systolic pressure measurements. (1998) (29)
Racial and ethnic differences in the risk of postpartum venous thromboembolism: a population‐based, case‐control study (2014) (28)
Nicotine induced haemodynamic changes during cigarette smoking and nicotine gum chewing: a placebo controlled study in young healthy volunteers. (1988) (28)
Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients (2019) (27)
Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. (1996) (27)
PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-CENTRE TRIAL OF KETANSERIN IN INTERMITTENT CLAUDICATION (1985) (27)
Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants (2008) (26)
Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study (2010) (26)
Hemodynamic effects of intermittent pneumatic compression of the lower limbs during laparoscopic cholecystectomy. (1995) (26)
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis (2005) (25)
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. (2016) (25)
Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. (1996) (25)
Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. (1996) (24)
Relationship between sympathetic reactivity and body weight loss in morbidly obese subjects (2004) (24)
Venous thromboembolism: why does ethnicity matter? (2011) (24)
Relationship between peripheral vascular disease and high plantar pressures in diabetic neuro-ischaemic patients. (2003) (23)
Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation (2011) (23)
Double‐blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants (2008) (23)
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. (2009) (23)
Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry (2019) (23)
Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients (2018) (22)
Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism (2017) (22)
Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism (2017) (22)
Effects of low-dose nifedipine on a cold provocation test in patients with Raynaud's disease. (1990) (22)
Management of venous leg ulcers. (1996) (22)
Digital sympathectomy (mictoarteriolysis) in the treatment of severe Raynaud's phenomenon secondary to systemic sclerosis (1997) (21)
Characterization of Human Late Outgrowth Endothelial Progenitor-Derived Cells under Various Flow Conditions (2011) (19)
Severe iatrogenic ergotism: incidence and clinical importance. (1991) (19)
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. (1985) (19)
Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon. (1984) (18)
Thrombolytic therapy compared with mechanical recanalization in non-acute peripheral arterial occlusions: a randomized trial. (1995) (18)
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. (2005) (18)
The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV‐077 is a more potent inhibitor of platelet function than aspirin (2011) (18)
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. (2014) (18)
The role of the D-dimer in the diagnosis of venous thromboembolism. (2000) (17)
Risk of falls and bleeding in elderly patients with acute venous thromboembolism (2014) (17)
Thrombolytic therapy in pulmonary embolism. (2001) (16)
Integrating Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism (1999) (16)
Direct oral anticoagulants for acute venous thromboembolism: closing the circle? (2014) (15)
Uptake of new treatment strategies for deep vein thrombosis: an international audit. (2004) (15)
Altered skin microcirculation in patients with systemic lupus erythematosus. (1997) (15)
Association Between Newborn Birth Weight and the Risk of Postpartum Maternal Venous Thromboembolism: A Population-Based Case–Control Study (2015) (15)
Diagnosis of Deep Vein Thrombosis by Combination of Doppler Ultrasound Flow Examination and Strain Gauge Plethysmography (1982) (15)
Direct oral anticoagulants: a guide for daily practice. (2016) (15)
Uses of low-molecular-weight heparin. (1995) (15)
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. (2020) (15)
Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease (2020) (14)
Life‐Threatening Pulmonary Embolism Associated with a Thrombus Straddling a Patent Foramen Ovale: Report of a Case (2008) (14)
PROTEIN C DEFICIENCY AND PREGNANCY: A CASE REPORT (1989) (13)
Effect of Standard and Low-Molecular Weight Heparin Fractions on Fibrinolysis and Platelet Aggregation in Patients Undergoing Hysterectomy (1986) (13)
Monitoring of Oral Anticoagulation by an Amidolytic Factor X Assay (1980) (13)
Outpatient percutaneous transluminal angioplasty for peripheral arterial disease. (1992) (13)
Postoperative deep vein thrombosis and surgery for varicose veins (1996) (13)
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. (2017) (13)
On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction. (2000) (13)
Swiss results from a global observational study of venous thromboembolism risk and prophylaxis use in the acute care hospital setting: analysis from the ENDORSE study. (2009) (12)
Postoperative Deep Venous Thrombosis (DVT) and Low-Molecular Weight Heparin (LMWH) Type and Dosage (1993) (12)
An evaluation of thromboembolism prophylaxis in acutely ill medical patients. (2002) (12)
Inability of serial fibrin monomer measurements to predict or exclude deep venous thrombosis in asymptomatic patients undergoing total knee arthroplasty. (2000) (11)
Differential Inhibition of Thrombin Activity and Thrombin Generation by a Synthetic Direct Thrombin Inhibitor (Napsagatran, Ro 46-6240) and Unfractionated Heparin in Patients with Deep Vein Thrombosis (1999) (11)
Ketanserin in chronic sympathetic dystrophy. An acute controlled trial (1984) (11)
Predictors of thromboprophylaxis in hospitalised medical patients (2015) (11)
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. (2018) (10)
Screening for proximal deep venous thrombosis using B-mode venous ultrasonography following major hip surgery: implications for clinical management. (1994) (10)
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE (2021) (10)
Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al. (2008) (10)
Generation of Human Inflammation-Resistant Endothelial Progenitor Cells by A20 Gene Transfer (2009) (10)
Thromboembolism and antithrombotic therapy in peripheral arterial disease. (1986) (10)
Women, thrombosis, and cancer: A gender-specific analysis. (2017) (10)
Acroosteolysis and Raynaud's phenomenon after vinyl chloride exposure. (1988) (10)
Inferior vena cava agenesis: Association with bilateral lower-limb deep vein thrombosis in young males (2009) (10)
Venography of the lower limbs. Pitfalls of the diagnostic standard. The ETTT Trial Investigators. (1992) (10)
Cellulitis and deep vein thrombosis: a controversial association (2003) (9)
Implementing Thrombosis Guidelines in Cancer Patients: A Review (2014) (9)
Assessment of peripheral arterial occlusive disease. (1999) (9)
Stroke secondary to multiple spontaneous cholesterol emboli. (1991) (8)
fixed-dose rivaroxaban is not associated with increased recurrent venous thromboembolism or major bleeding in patients with a high or low body weight : As099 (2015) (8)
One-year results of a smoking-cessation programme. (1999) (8)
Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. (1985) (8)
Caudal migration of the Günther vena caval filter. (1989) (8)
Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE (2021) (8)
Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). How we diagnose and treat deep vein thrombosis. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. (2004) (8)
[Drug treatment strategies for peripheral obliterative arteriopathy]. (1998) (7)
Venous Thrombosis: Risk Factors and Management (2007) (7)
Low molecular weight heparins and prevention of postoperative thrombosis (1989) (7)
Age-related rather than ulcer-related impairment of venous function tests in patients with venous ulceration. (1990) (7)
Severe ischemia of the hand following intra-arterial promazine injection: effects of vasodilation, anticoagulation, and local thrombolysis with tissue-type plasminogen activator. (1990) (7)
Effects of percutaneous transluminal angioplasty on skin microcirculation in patients with disabling peripheral arterial occlusive disease. (1994) (7)
LIVER CIRRHOSIS, ASCITES, AND PERIPHERAL VASCULAR RESISTANCE (1985) (7)
Transluminal angioplasty of the aorta, renal and mesenteric arteries in Takayasu arteritis: report of two cases. (1992) (7)
Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years (2019) (6)
Acute Effect of Ketanserin on the Leg Perfusion Assessed by Doppler Pressure Measurements and 201Tl Scintigraphy in Patients with Intermittent Claudication (1985) (6)
Secondary Prevention of Venous Thromboembolism: One Regimen May Not Fit All. (2015) (6)
Takayasu arteritis preceded by cardiac and cutaneous lesions. A case report. (1993) (6)
Severe vasospastic reactions (ergotism) during prophylactic administration of heparin-dihydroergotamine. (1987) (6)
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. (2021) (6)
[Control of oral anticoagulation: comparison between Quick and colorimetric factor X determination in 107 patients]. (1979) (6)
Recurrent, fatal pulmonary embolism despite inferior vena cava interruption with the Greenfield filter. (1987) (6)
THROMBOEMBOLISM AND AIR TRAVEL (1988) (5)
[Cystic adventitial degeneration of the popliteal artery: an unusual cause of intermittent claudication]. (1988) (5)
Doppler ultrasound and D-dimer (2012) (5)
More on: the early discoveries of collagen–platelet interaction and studies on its role in hemostatic plug formation (2005) (5)
Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study (2020) (5)
Coronary thrombolysis with clot-selective plasminogen activators. (1986) (5)
Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl. (1986) (4)
CLINICAL PREDICTION OF vTE RECURRENCE IN PATIENTS WITH PREvIOUS UNPROvOKED vENOUS THROMBOEMBOLISM. RESULTS FROM AN INDIvIDUAL-LEvEL META-ANALYSIS (2015) (4)
Deep venous thrombosis: an overview. (1988) (4)
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery (2002) (4)
Cyclosporine toxicity in renal transplant recipients detected by nailfold capillaroscopy with Na-fluorescein. (2000) (4)
Pharmacokinetics of human tissue-type plasminogen activator (t-PA) (1985) (3)
Thrombolytic therapy: can it prevent the development of post-thrombotic syndrome? (1998) (3)
Integrated diagnostic approach to suspected deep vein thrombosis and pulmonary embolism. (2002) (3)
Intravenous andintrapulmonary recombinant tissue-type plasminogen activator inthetreatment ofacutemassive pulmonary embolism (1988) (3)
Noninvasive Diagnosis of Deep Venous Thrombosis: Lesson from the Debate about Computerized Impedance Plethysmography (1992) (3)
Follow-up after partial interruption of the vena cava with the Günther filter (1990) (2)
Spontaneous haemorrhage in the iliopsoas muscle during oral anticoagulation. (1981) (2)
Systematic Review of Prognostic Factors and Treatment (2015) (2)
Faculty Opinions recommendation of American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. (2020) (2)
Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson index. Findings from the RIETE (2020) (2)
Control of Heparin Treatment with three Different Methods. Behaviour of Antithrombin III (1979) (2)
Clinical significance of a negative D‐dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry (2011) (2)
Prevention of venous thromboembolism after major abdominal surgery (1993) (2)
ASSESSMENT OF DIAGNOSIS OF DEEP VENOUS THROMBOSIS OF THE LOWER LIMBS USING ESTIMATION OF CLINICAL PROBABILITY (1987) (2)
Low-molecular-weight heparins: a decade with the new class of antithrombotic agents. (1994) (1)
Effects of Oxygen Inhalation on Skin Microcirculation in Patients With Peripheral Arterial Occlusive Disease (1992) (1)
[The treatment of deep venous thrombosis of the lower limbs]. (1988) (1)
[Value of the plasma measurement of D-dimers in the diagnosis of venous thromboembolism]. (1991) (1)
Trails of antiplatelet therapy (1994) (1)
[Role of D-dimers in the diagnosis of thromboembolic disease]. (1997) (1)
AbstractRivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017) (1)
Dicoumarin-Induced Skin Necrosis (2002) (1)
[The new antithrombotics in 2009]. (2009) (1)
[Endarterectomy using a Simpson catheter in arterial insufficiency of the lower limbs]. (1988) (1)
[D-dimer determination in suspected deep venous thrombosis or lung embolism]. (1997) (1)
Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism (2021) (1)
Segmental arterial calcification and atheromatosis in a limb with venous angiodysplasia (Klippel-Trenaunay syndrome). (1996) (1)
Overview of Direct Thrombin Inhibitors in Clinical Practice (2008) (1)
[Femoral artery thrombosis associated with heparin-induced thrombopenia]. (1986) (1)
First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry (2020) (1)
Aspirin for venous thromboembolism prevention and treatment: a renewal? (2012) (1)
[Use of antithrombotic agents in peripheral arterial diseases]. (1996) (1)
[Significance of the determination of D-dimers in venous thrombo-embolic disease]. (1992) (1)
[Does D-dimer determination allow the exclusion of pulmonary embolism?]. (1998) (1)
[Epidemiology and etiopathogenesis of deep venous thrombosis of the lower limbs]. (1990) (1)
[Treatment of severe asymptomatic carotid stenosis]. (1995) (1)
[Epidemiology and risk factors of venous thromboembolism]. (1992) (0)
P-080 Risk of venous thrombosis after Cesarean sections: a meta-analysis (2013) (0)
Subcutaneous or intravenous heparin for deep vein thrombosis. (1987) (0)
Low-MoIecuIar-We ight Hep ariglrl Pro p hyl axis and Therapyof Thromboembolic Diseases (1994) (0)
Fondaparinux Sodium A Review of its Use in the Prevention of Venous Thromboembolism Following Major Orthopaedic Surgery (2004) (0)
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. (2022) (0)
Central venous catheter thrombosis: prevention and treatment (1995) (0)
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery (2003) (0)
Landmarks in Anti-Thrombin Drug Development: The Argatroban Story (2008) (0)
[Definition and classification of vascular acro-syndromes]. (1992) (0)
STRATIFICATION DU RISQUE THROMBOEMBOLIQUE CHIRURGICAL (1999) (0)
[Selective thrombolysis of clots: effect of tissue-type plasminogen activator in the treatment of thromboembolic diseases]. (1987) (0)
Vascular medicine: breakthrough of a concept. (1999) (0)
[Pulmonary embolism and internal medicine]. (2011) (0)
Prevention of venous thromboembolism after major abdominal surgery. (1993) (0)
[Drug therapy of deep venous thrombosis]. (1996) (0)
2.1. Comparison of Six Different Methods for the Quantitative Assay of Antithrombin III (in English) (1977) (0)
[Hemorrhagic complications of anticoagulants in angiology]. (1994) (0)
Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor (2014) (0)
[Venous thromboembolism recurrence: is there a place for D-dimer?]. (2002) (0)
Paper1-10 jan 1998 (1998) (0)
Subcutaneous or intravenous heparin in treatment of deep vein thrombosis (1987) (0)
Clot-selective thrombolysis: the impact of tissue-type plasminogen activator (t-PA) in thromboembolic diseases. (1986) (0)
International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients (2012) (0)
Laboratory recognition of pulmonary embolism (1994) (0)
Abstract related to PL-22 Guidelines for antithrombotics in cancer patients (2012) (0)
Place des agents thrombolytiques en clinique (1990) (0)
Four weeks of enoxaparin reduces venous thrombosis after abdominal cancer compared with 1 week of treatment (2002) (0)
A COMPARATIVE ANALYSIS OF THE RESPONSE TO INFLAMMATORY STIMULI OF BLOOD- AND MESENCHYMAL STEM CELL-DERIVED ENDOTHELIAL PROGENITOR CELLS (2007) (0)
Author's reply (1996) (0)
Should patients with superficial thrombo phlebitis be investigated for deep venous thrombosis (1998) (0)
[Treatment of established venous thrombosis with low molecular weight heparins. A critical review]. (1991) (0)
[Thrombolysis in deep venous thrombosis: critical review]. (1991) (0)
Clinical value of transcutaneous oxygen tension (1999) (0)
Subject Index Vol. 14, 1994 (1994) (0)
ACP Journal Club. Ultrasonography-guided oral anticoagulant therapy reduced recurrent venous thromboembolism. (2009) (0)
Relationships of DVT with PE, PTS, superficial vein thrombosis and cellulitis (2014) (0)
[1998 update on deep vein thrombosis]. (1998) (0)
[Intracoronary thrombolysis or brief intravenous infusion of high-dose streptokinase in the treatment of acute myocardial infarction]. (1986) (0)
Long-term venous thromboembolism (VTE) recurrences and bleedings according to cancer site: Data from the RIETE registry. (2015) (0)
PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS (1986) (0)
Towards integrative, patient-centred clinical research (2021) (0)
[Diagnosis of deep venous thrombosis of the lower limbs: the role of clinical and paraclinical methods]. (1991) (0)
[Thrombolysis of cardiovascular diseases]. (1989) (0)
Ultrasonography-guided oral anticoagulant therapy reduced recurrent venous thromboembolism (2009) (0)
Contents, Vol. 14, 1994 (1994) (0)
[Treatment of deep venous thrombosis]. (1991) (0)
Systemic or Venous Thromboembolism Global Anticoagulant Registry in the Field – Venous Thromboembolism ( GARFIELD-VTE ) Rationale and design (2016) (0)
Clinical Predictors of Prophylaxis Use Prior to the Onset of Acute Venous Thromboembolism in Hospitalized Patients: Swiss Venous ThromboEmbolism Registry (SWIVTER) (2008) (0)
[Dissociation of human factor VIII and recombination of the fragments VIII-C and VIII-AG]. (1979) (0)
[The role of thrombolysis in the treatment of pulmonary embolism: indications and results]. (1991) (0)
Accuracy of strain-gauge plethysmography for the diagnosis of deep vein thrombosis. (1985) (0)
Deep Venous Thrombosis (2001) (0)
Corrigendum to “Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE” [Thromb. Res. 2020 Jul; 191:103–112] (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Henrim. Bounameaux?

Henrim. Bounameaux is affiliated with the following schools: